Dermatology: Molecular Mechanisms, Diagnosis and Therapeutic Targets

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".

Deadline for manuscript submissions: 5 February 2025 | Viewed by 1213

Special Issue Editors


E-Mail Website
Guest Editor
Dermatology Unit, Hospital Universitario Virgen de las Nieves, IBS Granada, 18002 Granada, Spain
Interests: dermatology; atopic dermatitis; biomarkers; skin barrier
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The skin is a unique sensory organ that can experience itch, pain, and other tactile nerve signals. Malfunctions or the dysregulation of skin homeostasis can contribute to a variety of skin diseases, such as psoriasis, atopic dermatitis, melanoma, and autoimmune diseases including vitiligo, alopecia, and scleroderma. Many dermatoses present a long and persistent clinical course and impact patients' quality of life. However, recent advances in pathogenesis analysis have led to new therapeutic approaches, such as specific biologics and other molecularly targeted drugs. Like other areas of medicine, the field of dermatology is now facing a new era of personalized therapies.

This Special Issue aims to explore the latest research advances in the etiology, molecular mechanisms, diagnosis, and personalized treatment of dermatological diseases. Both clinical and basic science research will be considered, and researchers are warmly invited to submit original research manuscripts and comments to give readers a deeper understanding of these complex diseases and a fresher perspective on the field.

Dr. Trinidad Montero-Vilchez
Prof. Dr. Salvador Arias-Santiago
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dermatologic diseases
  • atopic dermatitis
  • psoriasis
  • hidradenitis suppurativa
  • vitiligo
  • alopecia
  • melanoma
  • scleroderma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 3502 KiB  
Article
AKT and PERP Show Higher Expression in Precancerous than in Malignant Skin Neoplasms: Profiling in an Animal Model of Sequential Skin Carcinogenesis
by Efstathia Vairaktari, Alexander Schramm, Georgia Vairaktari, Spyridoula Derka, Frank Wilde, Andreas Sakkas, Christos Yapijakis, Maria Kouri, Athanasios Balakas, Andreas Lazaris, Marcel Ebeling and Stavros Vassiliou
J. Pers. Med. 2024, 14(8), 790; https://doi.org/10.3390/jpm14080790 - 25 Jul 2024
Viewed by 888
Abstract
The primary aim of this study was to evaluate the activation of the PERP and Akt oncogenes in the induction of skin cancer in FVB/N mice by a stepwise chemical process. Forty four-week-old female FVB/N mice were randomly divided into a control group [...] Read more.
The primary aim of this study was to evaluate the activation of the PERP and Akt oncogenes in the induction of skin cancer in FVB/N mice by a stepwise chemical process. Forty four-week-old female FVB/N mice were randomly divided into a control group (n = 8) and two experimental groups (group A: n = 16, group B: n = 16). In the study, the groups were subjected to a two-stage carcinogenesis procedure. This consisted of an initial application of 97.4 nmol DMBA to shaved skin on the back, followed by applications of 32.4 nmol TPA after thirteen weeks for group A and after twenty weeks for group B. The control group received no treatment. Skin conditions were monitored weekly for tumor development. At the end of the experiment, the animals were euthanized for further tissue sampling. Examination of the skin lesions in the experimental groups showed a correlation with tumor progression, ranging from dysplasia to carcinoma. Tumor samples were examined both histologically and immunohistochemically. Notably, and PERP expression was higher in precancerous than in malignant tumors. The differences in expression between precancerous and benign tumors provide further evidence of a role for PERP and Akt in the transition from benign to malignant states. Our findings underscore the critical roles of PERP and Akt in the pathogenesis of skin cancer and suggest their potential as biomarkers for early detection and targets for therapeutic intervention. Full article
(This article belongs to the Special Issue Dermatology: Molecular Mechanisms, Diagnosis and Therapeutic Targets)
Show Figures

Figure 1

Back to TopTop